X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs ORCHID PHARMA LTD - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD ORCHID PHARMA LTD LUPIN LTD/
ORCHID PHARMA LTD
 
P/E (TTM) x 28.0 -0.2 - View Chart
P/BV x 2.9 0.2 1,756.3% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 LUPIN LTD   ORCHID PHARMA LTD
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
ORCHID PHARMA LTD
Sep-13
LUPIN LTD/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs1,465194 755.2%   
Low Rs72735 2,077.4%   
Sales per share (Unadj.) Rs349.6276.5 126.4%  
Earnings per share (Unadj.) Rs5.6-79.2 -7.0%  
Cash flow per share (Unadj.) Rs29.6-43.5 -68.1%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs300.353.9 556.8%  
Shares outstanding (eoy) m452.0870.45 641.7%   
Bonus/Rights/Conversions ESOPSESOP-  
Price / Sales ratio x3.10.4 757.0%   
Avg P/E ratio x197.2-1.4 -13,642.5%  
P/CF ratio (eoy) x37.1-2.6 -1,406.3%  
Price / Book Value ratio x3.62.1 171.9%  
Dividend payout %90.00-   
Avg Mkt Cap Rs m495,5028,067 6,142.7%   
No. of employees `00017.02.8 608.6%   
Total wages/salary Rs m28,6472,527 1,133.6%   
Avg. sales/employee Rs Th9,273.66,956.1 133.3%   
Avg. wages/employee Rs Th1,681.0902.5 186.3%   
Avg. net profit/employee Rs Th147.4-1,993.0 -7.4%   
INCOME DATA
Net Sales Rs m158,04219,477 811.4%  
Other income Rs m1,504407 369.2%   
Total revenues Rs m159,54519,884 802.4%   
Gross profit Rs m31,4751,103 2,854.6%  
Depreciation Rs m10,8592,519 431.0%   
Interest Rs m2,0445,227 39.1%   
Profit before tax Rs m20,076-6,236 -321.9%   
Minority Interest Rs m-7120 -359.9%   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,644511 -2,865.7%   
Tax Rs m2,885-125 -2,304.0%   
Profit after tax Rs m2,513-5,580 -45.0%  
Gross profit margin %19.95.7 351.8%  
Effective tax rate %14.42.0 715.7%   
Net profit margin %1.6-28.7 -5.5%  
BALANCE SHEET DATA
Current assets Rs m122,09511,014 1,108.5%   
Current liabilities Rs m50,95632,060 158.9%   
Net working cap to sales %45.0-108.1 -41.7%  
Current ratio x2.40.3 697.5%  
Inventory Days Days8595 89.2%  
Debtors Days Days12034 357.4%  
Net fixed assets Rs m129,87629,440 441.2%   
Share capital Rs m904705 128.3%   
"Free" reserves Rs m134,8662,043 6,602.7%   
Net worth Rs m135,7713,800 3,573.0%   
Long term debt Rs m64,2459,018 712.4%   
Total assets Rs m263,05446,510 565.6%  
Interest coverage x10.8-0.2 -5,605.1%   
Debt to equity ratio x0.52.4 19.9%  
Sales to assets ratio x0.60.4 143.5%   
Return on assets %1.7-0.8 -227.9%  
Return on equity %1.9-146.9 -1.3%  
Return on capital %3.7-3.7 -99.6%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m53,1417,513 707.3%   
Fx outflow Rs m19,3355,649 342.3%   
Net fx Rs m33,8071,865 1,813.2%   
CASH FLOW
From Operations Rs m17,5121,682 1,041.3%  
From Investments Rs m-14,073-9,860 142.7%  
From Financial Activity Rs m-14,9216,644 -224.6%  
Net Cashflow Rs m-11,482-1,535 748.0%  

Share Holding

Indian Promoters % 46.6 32.3 144.3%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 4.6 245.7%  
FIIs % 31.9 3.3 966.7%  
ADR/GDR % 0.0 4.6 -  
Free float % 10.1 55.3 18.3%  
Shareholders   98,259 84,811 115.9%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   SANOFI INDIA  ABBOTT INDIA  FRESENIUS KABI ONCO.  WYETH LTD  GSK PHARMA  

Compare LUPIN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Related Views on News

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Sep 25, 2018 03:37 PM

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - SHASUN PHARMA COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS